- Home
- BDTX vs SEVN Comparison
BDTX vs SEVN Comparison
Compare BDTX & SEVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | SEVN |
|---|---|---|
| Founded | 2014 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 187.6M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | BDTX | SEVN |
|---|---|---|
| Price | $1.76 | $8.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $9.67 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 2.1M | 82.8K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 13.90% |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $29,383,000.00 |
| Revenue This Year | N/A | $27.75 |
| Revenue Next Year | N/A | $4.06 |
| P/E Ratio | ★ N/A | $44.21 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.78 | $7.90 |
| 52 Week High | $4.94 | $12.85 |
Technical Indicators
Market Signals| Indicator | BDTX | SEVN |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 49.73 |
| Support Level | N/A | $8.33 |
| Resistance Level | $2.30 | $8.83 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 5.41 | 16.67 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.